bioRxiv Science⌕ Search

Biology subjects

Mane-Damas, M.

Publications and source records attributed to Mane-Damas, M..

2 recordsLinked to original sources

Hock immunization: a refined alternative for developing Experimental Autoimmune Myasthenia Gravis (EAMG) in mice.

Experimental autoimmune myasthenia gravis (EAMG) is an active-immunization model that was first discovered by coincidence when rabbits injected with purified acetylcholine receptor for neuromuscular junction physiology studies, suddenly developed muscle weakness. In mice, this model typically involves bilateral subcutaneous injections of purified torpedo acetylcholine receptor (tAChR) in the hind footpads and the scapular regions, followed by one or two booster immunizations in the thighs and over the scapulas. However, footpad injections can cause severe discomfort and progressive debilitation. Hock immunization has shown to be a viable alternative in other models, offering comparable efficacy without impairing mobility caused by inflammation, thus reducing discomfort. To investigate the use of hock immunization in the mouse EAMG model, 7-week-old female C57BL6/6J (B6) mice were bilaterally injected over the scapulas and either in the hocks or footpads for the primary immunization. All animals received a booster immunization 4 weeks later, following standard guidelines. Inverted mesh measurements demonstrated that tAChR-immunized animals whether receiving hock or footpad injections, exhibited similar muscle weakness. This weakness correlated with reduced body weight, which reached statistical significance, only in the hock-immunized group. tAChR antibodies were detectable in both groups 4 weeks after primary immunization and continue raising until the end of the experiment. Additionally, tAChR immunized mice required significantly less curare to achieve decrement in muscle response. Notably, hock-immunized mice displayed consistent mechanical sensitivity over time, which was significantly lower compared to footpad-immunized mice. In conclusion, hock-immunization is a refined and effective alternative for developing the EAMG mouse model. It results in similar disease incidence and severity while minimizing immunization-related discomfort compared to the standard footpad method.

immunology↗

Isolation and characterization of rare circulating autoantibody-producing cells from patients with muscle-specific kinase myasthenia gravis

Myasthenia gravis (MG) is a chronic autoimmune disorder characterized by muscle weakness and caused by autoantibodies that bind to functional membrane proteins at the neuromuscular junction. Most patients have autoantibodies to the acetylcholine receptor (AChR), but a subset of patients instead have autoantibodies to muscle specific tyrosine kinase (MuSK). MuSK is an essential component of the Agrin/Lipoprotein receptor-related protein 4(LRP4)/MuSK/downstream of tyrosine kinase 7 (DOK7) pathway that is responsible for synaptic differentiation, including clustering of AChRs at the neuromuscular junction, both during development and in adult muscle. Nerve-released Agrin binds to LRP4 which then binds to MuSK, stimulating autophosphorylation and recruitment of DOK7 to complete the membrane component of the pathway. Serum-derived IgG4 subclass MuSK autoantibodies prevent the binding of LRP4 to MuSK, subsequently impairing autophosphorylation, resulting in the loss of Agrin-induced AChR clustering in the mouse myotube-forming C2C12 line. Although this autoimmune mechanism appears well understood, MuSK autoantibodies from patients are polyclonal. Most are IgG4 but IgG1, 2 and 3 are also present and can achieve similar results on AChR clustering. In addition, most bind the first Ig-like domain in MuSK, however some patients harbor serum autoantibodies that recognize other domains in MuSK. We sought to establish individual MuSK IgG clones so that the disease mechanisms could be better understood. We isolated MuSK autoantibody-expressing B cells from MuSK MG patients with a fluorescent-tagged MuSK antigen multimer and generated a panel of human monoclonal autoantibodies (mAbs) from these cells. We produced 77 mAbs from single B cells collected from six MuSK MG patients. Here we focused on three highly specific mAbs that bound quantitatively to MuSK in solution, to MuSK-expressing HEK cells and at mouse neuromuscular junctions where they co-localized with AChRs. These three IgG isotype mAbs (two IgG4 and one IgG3 subclass) recognized the Ig-like domain 2 of MuSK. The three MuSK mAbs inhibited Agrin induced-AChR clustering in C2C12 myotubes, but intriguingly, they enhanced rather than inhibited MuSK phosphorylation. This approach for ex vivo isolation of MuSK MG autoantibody-producing cells and production of human recombinant mAbs has identified distinct autoantibody specificities and likely divergent effector mechanisms. Collectively, these findings will enable a better understanding of MuSK autoantibody-mediated pathology.

immunology↗